Drug-eluting stents: results, promises and problems
| Autor: | Ernst E. van der Wall, Paul H.A. Quax, J. Wouter Jukema, Nuno Pires, Bart J.M. van Vlijmen, Martin J. Schalij, Pranobe V. Oemrawsingh, Hazem M. Warda, Barend L. van der Hoeven |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Drug
medicine.medical_specialty Percutaneous media_common.quotation_subject medicine.medical_treatment Coronary Restenosis chemistry.chemical_compound Drug Delivery Systems Restenosis medicine Humans cardiovascular diseases Antibacterial agent media_common business.industry equipment and supplies medicine.disease Review article Surgery surgical procedures operative Paclitaxel chemistry Drug-eluting stent Sirolimus Stents Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | International Journal of Cardiology. 99:9-17 |
| ISSN: | 0167-5273 |
| DOI: | 10.1016/j.ijcard.2004.01.021 |
| Popis: | In-stent restenosis is the major drawback of percutaneous coronary interventions, occurring in 10-40% of the patients. Recently, new stents have emerged which are loaded with anti-inflammatory, anti-migratory, anti-proliferative or pro-healing drugs. These drugs are supposed to inhibit inflammation and neointimal growth and subsequently in-stent restenosis. In this review article the results of human clinical studies investigating drug-eluting stents are discussed from a clinical point of view, focussing on the efficacy in the prevention of restenosis and their potential side effects. Both success and failure in the field of drug-eluting stents have been described. Successful devices are the sirolimus-eluting and the polymer-based paclitaxel-eluting stents. Potentially dangerous side effects of drug-eluting stents are adverse drug interactions, incomplete stent apposition and increased in-stent thrombosis rates. Demonstration of long-term efficacy is mandatory since in some animal studies a delayed healing has been observed. Currently, the successful drug-eluting stents are under investigation in all types of lesions. We conclude that the results with some drug-eluting stents are promising, but further evidence on long-term efficacy and safety, also in high-risk subgroups, is needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect